12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enhanced TCR Therapy for MM: Preliminary Phase I/II data

Preliminary data from 13 evaluable MM patients in a single-arm, open-label, U.S. Phase I/II trial showed that enhanced TCR therapy given in conjunction with autologous stem cell transplantation led to an ORR of 77% at day 100. Of the 15 patients treated to date, 10 have ongoing responses and 5...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >